TY  - JOUR
AU  - Phipps, Amanda I
AU  - Alwers, Elizabeth
AU  - Harrison, Tabitha
AU  - Banbury, Barbara
AU  - Brenner, Hermann
AU  - Campbell, Peter T
AU  - Chang-Claude, Jenny
AU  - Buchanan, Daniel
AU  - Chan, Andrew T
AU  - Farris, Alton B
AU  - Figueiredo, Jane C
AU  - Gallinger, Steven
AU  - Giles, Graham G
AU  - Jenkins, Mark
AU  - Milne, Roger L
AU  - Newcomb, Polly A
AU  - Slattery, Martha L
AU  - Song, Mingyang
AU  - Ogino, Shuji
AU  - Zaidi, Syed H
AU  - Hoffmeister, Michael
AU  - Peters, Ulrike
TI  - Association Between Molecular Subtypes of Colorectal Tumors and Patient Survival, Based on Pooled Analysis of 7 International Studies.
JO  - Gastroenterology
VL  - 158
IS  - 8
SN  - 0016-5085
CY  - Philadelphia, Pa. [u.a.]
PB  - Saunders
M1  - DKFZ-2020-00463
SP  - 2158-2168.e4
PY  - 2020
N1  - 2020 Jun;158(8):2158-2168.e4 / #EA:C070#LA:C070#
AB  - The heterogeneity among colorectal tumors is probably due to differences in developmental pathways and might associate with patient survival times. We studied the relationship among markers of different subtypes of colorectal tumors and patient survival.We pooled data from 7 observational studies, comprising 5010 patients with colorectal cancer. All the studies collected information on microsatellite instability (MSI), CpG island methylator phenotype (CIMP), and mutations in KRAS and BRAF in tumors. Tumors with complete marker data were classified as type 1 (MSI high, CIMP positive, with pathogenic mutations in BRAF but not KRAS), type 2 (not MSI high, CIMP positive, with pathogenic mutations in BRAF but not KRAS); type 3 (not MSI high or CIMP, with pathogenic mutations in KRAS but not BRAF); type 4 (not MSI-high or CIMP, no pathogenic mutations in BRAF or KRAS), or type 5 (MSI-high, no CIMP, no pathogenic mutations in BRAF or KRAS). We used Cox regression to estimate hazard ratios (HR) and 95
LB  - PUB:(DE-HGF)16
C6  - pmid:32088204
DO  - DOI:10.1053/j.gastro.2020.02.029
UR  - https://inrepo02.dkfz.de/record/153797
ER  -